NCT05034770View on ClinicalTrials.gov

Effectiveness of Major Ozone Autohemotherapy in the Treatment of Fibromyalgia Syndrome

CompletedOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

January 10, 2022

Study Completion Date

January 11, 2022

Conditions
Fibromyalgia Syndrome
Interventions
OTHER

major ozone autohemotherapy

This treatment is based on treating 100 ml of the pa- tient's blood with 100 ml of O3 followed by reinfusion in the donor, in a fast procedure. Each patient received 10 sessions of autohemotherapy with O3 twice a week.

Trial Locations (1)

Unknown

Private Medar Hospital, Kocaeli

All Listed Sponsors
lead

Emine Dundar Ahi, MD

OTHER

NCT05034770 - Effectiveness of Major Ozone Autohemotherapy in the Treatment of Fibromyalgia Syndrome | Biotech Hunter | Biotech Hunter